A Study of NTX-1472 in Social Anxiety Disorder
Recruiting
Phase 2
Interventional Study
Social Anxiety Disorder (SAD)
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 100 (estimated)
- Sponsor
- Newleos Therapeutics, Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are:
* Is NTX-1472 safe and well tolerated in adults with SAD?
* How effectively does NTX-1472 treat adults with SAD?
Researchers will compare the effects of NTX-1472 with matching plac…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Key Inclusion Criteria
* Has provided written informed consent for the study and is willing to comply with all requirements of the protocol
* English speaker
* Male or female, ≥18 and ≤65 years of age
* Current diagnosis of generalized Social Anxiety Disorder (SAD) as defined by the Diagnostic and …
Contacts